SomnoMed Crecimiento futuro

Future controles de criterios 1/6

Se prevé que los ingresos de SomnoMed aumenten en un 9.7% al año.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.7%
Tasa de crecimiento de los ingresos	9.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	25 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 15

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

Nov 18

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Sep 27

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

May 10

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Oct 26

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

May 12

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Mar 02

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Feb 01

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Dec 28

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Dec 01

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

Jul 28

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Jul 14

Previsiones de crecimiento de beneficios e ingresos

ASX:SOM - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	113	N/A	N/A	N/A	1
6/30/2025	103	N/A	N/A	N/A	1
6/30/2024	93	N/A	N/A	N/A	1
12/31/2023	89	-11	-10	-5	N/A
9/30/2023	86	-9	-10	-4	N/A
6/30/2023	84	-8	-10	-4	N/A
3/31/2023	81	-7	-11	-3	N/A
12/31/2022	79	-5	-11	-2	N/A
9/30/2022	76	-5	-9	0	N/A
6/30/2022	73	-4	-7	2	N/A
3/31/2022	69	-5	-6	1	N/A
12/31/2021	66	-5	-6	-1	N/A
9/30/2021	64	-3	-4	1	N/A
6/30/2021	63	-1	-1	3	N/A
3/31/2021	59	-1	2	5	N/A
12/31/2020	55	-1	5	7	N/A
9/30/2020	56	-1	4	6	N/A
6/30/2020	57	0	3	5	N/A
3/31/2020	60	0	0	2	N/A
12/31/2019	63	1	-4	-1	N/A
9/30/2019	61	0	-6	-4	N/A
6/30/2019	59	0	-8	-7	N/A
3/31/2019	58	2	N/A	N/A	N/A
12/31/2018	56	3	-9	-7	N/A
9/30/2018	54	3	-10	-8	N/A
6/30/2018	52	2	-12	-9	N/A
3/31/2018	51	-1	N/A	N/A	N/A
12/31/2017	50	-4	-11	-8	N/A
9/30/2017	50	-4	N/A	-5	N/A
6/30/2017	49	-3	N/A	-3	N/A
3/31/2017	48	-2	N/A	-1	N/A
12/31/2016	47	-1	N/A	0	N/A
9/30/2016	45	0	N/A	1	N/A
6/30/2016	44	0	N/A	2	N/A
3/31/2016	42	0	N/A	2	N/A
12/31/2015	39	1	N/A	1	N/A
9/30/2015	37	1	N/A	0	N/A
6/30/2015	34	1	N/A	0	N/A
3/31/2015	34	1	N/A	0	N/A
12/31/2014	35	1	N/A	-1	N/A
9/30/2014	32	1	N/A	-1	N/A
6/30/2014	30	0	N/A	-1	N/A
3/31/2014	26	0	N/A	0	N/A
12/31/2013	22	0	N/A	0	N/A
9/30/2013	20	0	N/A	0	N/A
6/30/2013	18	1	N/A	1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de SOM es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de SOM crezcan más rápidamente que el mercado Australian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de SOM crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (10.9% al año) de SOM crezcan más rápidamente que los del mercado Australian (4.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.9% al año) de SOM crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SOM se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

SomnoMed Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 25% to AU$2.07

Price target decreased by 12% to AU$1.88

Consensus forecasts updated

Consensus forecasts updated

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Recent updates

New major risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

Price target increased by 25% to AU$2.07

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.498845 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Full year 2023 earnings: Revenues in line with analyst expectations

New minor risk - Financial data availability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Price target decreased by 12% to AU$1.88

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS misses analyst expectations

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

No independent directors

Global CEO recently sold AU$81k worth of stock

SomnoMed Introduces Rest Assure

First half 2022 earnings: EPS and revenues miss analyst expectations

SomnoMed Introduces Rest Assure

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought AU$499k worth of stock

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)

New 90-day low: AU$1.83

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020

New 90-day high: AU$2.45

Full year earnings released - AU$0.0069 loss per share

New 90-day high: AU$2.14

Chairman of the Board recently bought AU$203k worth of stock

New 90-day high - AU$1.58

Full year earnings released

SomnoMed Limited to Report Fiscal Year 2020 Results on Aug 24, 2020

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento